United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024
07 Dezembro 2023 - 8:00AM
Business Wire
United Therapeutics (Nasdaq: UTHR), a public benefit
corporation, today announced that the company has been named on
Newsweek’s list of America’s Most Responsible Companies
2024. This award is presented by Newsweek and Statista Inc.,
the world-leading statistics portal and industry ranking provider.
The list of awards was announced on December 6, 2023, is available
on Newsweek’s website, and recognizes the top 600 most responsible
companies in the United States, spanning 14 industries.
America’s Most Responsible Companies were selected based on
publicly available key performance indicators derived from
Corporate Social Responsibility Reports and Sustainability Reports,
as well as an independent survey asking U.S. residents about their
perception of company activities related to corporate social
responsibility. The key performance indicators focused on company
performance in the environmental, social, and corporate governance
areas, while the independent survey asked U.S. citizens about their
perception of company activities related to corporate social
responsibility.
United Therapeutics’ 2023 Corporate Responsibility and Public
Benefit Report can be found at
corporateresponsibility.unither.com.
“Maintaining the trust of all our stakeholders – our
shareholders, patients, employees, and the communities in which we
live and work – is core to our purpose and success,” said
Martine Rothblatt, Ph.D., Chairperson and Chief Executive
Officer of United Therapeutics Corporation. “We are honored to be
named among America’s Most Responsible Companies by Newsweek and
Statista again this year, which reinforces our efforts as a public
benefit corporation to operate responsibly and as a careful steward
of all of our capital – human, natural, and financial.”
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use
our enthusiasm, creativity, and persistence to innovate for the
unmet medical needs of our patients and to benefit our other
stakeholders. We are bold and unconventional. We have fun; we do
good. We are the first publicly traded biotech or pharmaceutical
company to take the form of a public benefit corporation. Our
public benefit purpose is to provide a brighter future for patients
through the development of novel pharmaceutical therapies; and
technologies that expand the availability of transplantable
organs.
You can learn more about what it means to be a PBC here:
unither.com/pbc.
Forward-looking Statements
Statements included in this press release that are not
historical in nature are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, our efforts to
innovate for the unmet medical needs of our patients, to benefit
our other stakeholders, and to pursue our public benefit purpose of
developing novel pharmaceutical therapies and technologies that
expand the availability of transplantable organs. These
forward-looking statements are subject to certain risks and
uncertainties, such as those described in our periodic reports
filed with the Securities and Exchange Commission, that could cause
actual results to differ materially from anticipated results.
Consequently, such forward-looking statements are qualified by the
cautionary statements, cautionary language, and risk factors set
forth in our periodic reports and documents filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. We claim the protection of the safe
harbor contained in the Private Securities Litigation Reform Act of
1995 for forward-looking statements. We are providing this
information as of December 7, 2023 and assume no obligation to
update or revise the information contained in this press release
whether as a result of new information, future events or any other
reason.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231207991712/en/
Catherine Sheehy at (240) 398-3504 (corporate responsibility)
Dewey Steadman at (202) 919-4097 (investors/media)
https://ir.unither.com/contact-ir
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024